Menu Search
Equities

Prescient Therapeutics Ltd

PTX:ASX

Prescient Therapeutics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.039
  • Today's Change-0.001 / -2.50%
  • Shares traded149.46k
  • 1 Year change-37.10%
  • Beta1.5981
Data delayed at least 20 minutes, as of Sep 20 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Prescient Therapeutics Ltd had net income fall 17.61% from a loss of 7.00m to a larger loss of 8.24m despite a 49.77% increase in revenues from 459.10k to 687.58k.
Gross margin--
Net profit margin-1,198.14%
Operating margin-1,194.87%
Return on assets-33.97%
Return on equity-37.32%
Return on investment-37.31%
More ▼

Cash flow in AUDView more

In 2024, Prescient Therapeutics Ltd increased its cash reserves by 77.99%, or 4.60m. Cash Flow from Investing totalled 12.00m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 7.40m for operations while cash generated from financing totalled 18.15k.
Cash flow per share--
Price/Cash flow per share--
Book value per share0.0224
Tangible book value per share0.0204
More ▼

Balance sheet in AUDView more

Prescient Therapeutics Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio8.08
Quick ratio--
Total debt/total equity0.0183
Total debt/total capital0.018
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.